Hydroxychloroquine

Prescription immunosuppressant use is low during the first year of care among young patients with newly diagnosed systemic lupus erythematosus, while hydroxychloroquine use is prevalent, although not universal, researchers report.

Published earlier this month in The New England Journal of Medicine is yet another well-conducted study that demonstrates lack of efficacy of hydroxychloroquine against COVID-19.

The COVID-19 pandemic has had “a tremendously negative impact” on efforts to eliminate hepatitis C, according to Ricardo Franco, MD.

Efficacy of hydroxychloroquine to reduce recurrence rate of congenital heart block.

New data showed that hydroxychloroquine combined with other COVID-19 treatments may increase the risk for mortality among patients with cancer. It was the top story in hematology/oncology last week.

Hydroxychloroquine in combination with other treatments for COVID-19 appeared associated with increased mortality among patients with cancer, study results showed.

Hydroxychloroquine, by itself or with azithromycin, did not improve the clinical status of patients with mild to moderate COVID-19, according to results from a randomized controlled trial published in The New England Journal of Medicine.

In patients treated with hydroxychloroquine, multifocal electroretinography could detect abnormalities in macular function early, before overt maculopathy was present, according to a study.

In a cohort of pregnant women with prior maternal congenital heart block, hydroxychloroquine successfully reduced the risk for recurrent fetal blocks by more than 50%, according results from the PATCH trial.

Dispensed prescriptions of hydroxychloroquine in the U.S. increased 86.2%, while such prescriptions of chloroquine increased 158.6% from February to March 2020, data show.